Rapid versus conventional glucocorticoid tapering in pure membranous lupus nephritis: a multicenter retrospective study
Clicks: 6
ID: 324388
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
6 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #17 of 46 articles by views in Rheumatology Advances in Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives While recent guidelines recommend early glucocorticoid (GC) tapering for lupus nephritis (LN), supporting evidence for pure membranous LN remains limited. The present study investigated the impact of rapid GC tapering on renal outcomes in this population. Methods We performed a multicenter retrospective study across 16 centers in Japan, including 67 patients with biopsy-proven pure membranous LN who initiated GC therapy between 2003 and 2023. Patients were classified into rapid tapering (GC dose ≤7.5 mg/day at 6 months) and conventional tapering (>7.5 mg/day at 6 months) groups. The primary endpoint was the partial renal response (PRR) at 12 months. Secondary endpoints included the complete renal response (CRR), relapse, and severe adverse events (SAEs). Adjusted risk ratios (aRRs) were estimated using modified Poisson regression models for failure to achieve PRR/CRR. Results Fifteen patients underwent rapid tapering and 52 conventional tapering. Baseline characteristics were generally comparable. At 12 months, PRR was achieved in 85.7% of the rapid group and 84.3% of the conventional group (aRR for failure 1.04; 95% confidence interval [CI] 0.17-6.39). CRR rates at 12 months were 64.3 and 56.9%, respectively (aRR for failure 0.90; 95% CI 0.40-2.02). At 24 months, PRR and CRR did not differ statistically between groups. Relapse occurred in 20.0% versus 7.7% (p = 0.185). No SAEs were reported in the rapid group, while three occurred in the conventional group. Conclusions Rapid GC tapering to ≤ 7.5 mg/day at 6 months appeared feasible in a subset of patients with pure membranous LN, but the findings are preliminary and should be interpreted cautiously because of the small rapid-taper group and imprecise estimates.
| Reference Key |
openalex_W7201999820
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Hidekazu Ikeuchi, Keiju Hiromura, Yoshiya Tanaka, Hiroko Sato, Koichiro Ohmura, Hiroki Hayashi, K. Hiramoto, Akiho Iwashita, Shinsuke Yasuda, Shinya Kaname, Yutaka Kawahito, Hiromi Shimada, Tomohiro Koga, Isao Matsumoto, Masahiro Ayano, Kazuro Kamada, Shoichi Maruyama, Tomonori Ishii, Satoshi Kubo, Shingo Nakayamada, Hayato Shimizu, Shuji Sumitomo, Yukio Yuzawa, Yuko Kaneko, Hironari Hanaoka, Akira Ōnishi, Akio Morinobu, Tadashi Hosoya, Taiki Yamaguchi, Takahisa Kawakami, Aki Sakashita, Takahiro Seno, Takashi Kida, Hiroaki Dobashi, Takuya Tomokawa, Atsushi Kawakami, Yuya Kondo, Hiroaki Niiro, Michihito Kono, Sawako Kato, Kayaho Maeda, Tatsuya Atsumi |
| Journal | Rheumatology Advances in Practice |
| Year | 2026 |
| DOI |
10.1093/rap/rkag096
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.